Skip to main content
Caplight Logo









NKILT Therapeutics

NKILT Therapeutics

Private
Houston, TexasHealthcare & Life Scienceshttps://nkilt.com/

Last Round

Accelerator

Sep 19, 2022

Momentum

Top 50%

of companies Caplight tracks

Company Overview

NKILT Therapeutics is a biotechnology company developing allogeneic, off-the-shelf natural killer (NK) cell therapies for the treatment of leukemias and solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

cell therapynatural killer cellsNK cellsallogeneic therapyoff-the-shelf therapyHLA-G pathwaychimeric ILT-receptorCIR technologycancer immunotherapyoncology biotechimmune checkpointdrug discoverysolid tumor treatmentleukemia therapynext-gen immunotherapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NKILT Therapeutics Comparables

Compare NKILT Therapeutics with similar companies based on industry and business-model similarity.

NKILT Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Shoreline Biosciences
86%
Invectys
81%
Indapta Therapeutics
79%

NKILT Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorSep 19, 2022

Key People

Founding team and executive leadership

MSc Raphaël G. Ognar

President & CEO, Co-Founder - Chairman of the Board

Founding Team

NKILT Therapeutics Investors

Notable investors and investment history

NKILT Therapeutics investors
InvestorRounds
The Innovation SpaceAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 17, 2026

    Monthly visitors grew 197% MoM, reaching 2K.

  • May 2, 2025

    Monthly visitors increased 73% MoM.

NKILT Therapeutics Filings

Explore SEC and related filing metadata, where available.

NKILT Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about NKILT Therapeutics's valuation, stock price, and market status.

Is NKILT Therapeutics a public or private company?

NKILT Therapeutics is a private company.

What is the current stock price of NKILT Therapeutics?

NKILT Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is NKILT Therapeutics worth (valuation)?

Valuation information for NKILT Therapeutics is not publicly available.

Can I buy NKILT Therapeutics stock?

NKILT Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was NKILT Therapeutics's last funding round?

NKILT Therapeutics's most recent funding round was Accelerator on September 19, 2022.

Who are the main investors in NKILT Therapeutics?

Key investors in NKILT Therapeutics include The Innovation Space.

Will NKILT Therapeutics IPO soon?

No public IPO plans have been announced for NKILT Therapeutics.

How can I track NKILT Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor NKILT Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHouston, Texas
Employee Range6
Year Founded2021
Last FundingSep 19, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?